HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition

Pre-IPO Kindstar Globalgene Technology - A New Start with More Challenges

Pre-IPO Shanghai Bio-Heart Biological Technology - Here Are the Strength and Concerns

Remegen Co Ltd (9995.HK) - Commercialized RC18 + IPO On SSE STAR Market = New Chapter & Challenges

Pre-IPO Angelalign Technology - Promising Market but Full of Challenges

Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Acotec Scientific Holdings / Equity Capital Markets

<p>With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, <a href="https://www.smartkarma.com/entities/acotec-scientific-holdings-limited" target="_blank" data-smartkarma-citation="entities:32176:1" rel="noopener">Acotec Scientific Holdings (ASH HK)</a> applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.</p>

With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, Acotec Scientific Holdings (ASH HK) applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.

Shanghai MicroPort Endovascula (688016 CH)

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges